ALKERMES (ALKS)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ALKS
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALKS | Director; Chief Medical Officer | 60 | ["Chief Medical Officer of Wave Life Sciences Ltd.","Chief Medical Officer of Ring Therapeutics, Inc.","Chief Medical Officer of AavantiBio, Inc.","Senior Vice President, Chief Medical Officer of Cyclerion Therapeutics, Inc.","Senior Vice President, Chief Development Officer of Ironwood","Senior Vice President, Chief Medical Officer of Axcella Health Inc.","Senior Vice President of Global Medicines Development and Affairs at Vertex Pharmaceuticals Incorporated","Associate Professor of Neurology at Harvard Medical School","Practicing neurologist at Brigham and Women’s Hospital for 20 years","Scientific Advisor for Cyclerion","Experience in drug development, clinical and medical research"] | ["Audit and Risk","Compensation","Audit and Risk Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Since May 2025, Dr. Wright has served as Chief Medical Officer of Wave Life Sciences Ltd., a publicly-traded biotechnology company focused on developing RNA-targeting medicines. Prior to that, Dr. Wright served as Chief Medical Officer of gene therapy companies Ring Therapeutics, Inc. from February 2023 to May 2025 and AavantiBio, Inc. from May 2021 through its acquisition by Solid Biosciences Inc. in December 2022. From April 2019 to March 2021, Dr. Wright served as Senior Vice President, Chief Medical Officer of Cyclerion Therapeutics, Inc. ( Cyclerion ), a publicly-traded spin-off from Ironwood Pharmaceuticals, Inc. ( Ironwood ), where he led global development functions across therapeutic areas. From March 2017 to April 2019, Dr. Wright served as Senior Vice President, Chief Development Officer of Ironwood. Prior to that, Dr. Wright served as Senior Vice President, Chief Medical Officer of Axcella Health Inc. and Senior Vice President of Global Medicines Development and Affairs at Vertex Pharmaceuticals Incorporated, where he led global development functions across therapeutic areas. Dr. Wright was previously an Associate Professor of Neurology at Harvard Medical School and was a practicing neurologist at Brigham and Women s Hospital for 20 years. He previously served as a Scientific Advisor for Cyclerion. Dr. Wright earned his A.B. in Biochemical Sciences from Harvard University, his M.D. in Medicine and Neuroscience from Harvard Medical School, his Ph.D. in Neuroanatomy from Vrije Universiteit and his MMSc. in Clinical Investigation from Harvard Medical School. Qualifications and Skills: Dr. Wright is a highly accomplished scientific and medical leader in the academic and biopharmaceutical communities with nearly three decades of drug development, clinical and medical research experience in diseases of the central nervous system. The Board benefits from his significant expertise in the field of neuroscience, his extensive service in executive leadership positions at publicly-traded companies overseeing global drug development functions across therapeutic areas, including regulatory affairs, clinical development and operations, pharmaceutical development, and securing approval of new therapies, and his background as a practicing neurologist.